8-K - PKTX - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the SecuritiesExchange Act of 1934

Date of Report: November21, 2025

ProtoKinetix, Incorporated

(Exact name of registrant as specified in its charter)

Nevada	000-32917	94-3355026
State<br>of Incorporation	Commission<br><br> <br>File Number	IRS<br>Employer<br><br> <br>Identification<br>Number

109W Main Street,

Dalton, OH 44618

Address of principal

executive offices

330-445-4971

Telephone number,

including Area Code

_______________________________

Former name or former address if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A

Item 7.01. Regulation FD Disclosure.

On November 21, 2025, ProtoKinetix, Incorporated (the “Company”) sent out a Company update to its stockholders. The full text of the update referenced herein is furnished hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 7.01 of the Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Company update
104	Cover Page Interactive<br> Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 21st day of November 2025.

ProtoKinetix, Inc.
By:	/s/ Michael Guzzetta
	Michael Guzzetta, President, CEO & CFO

EXHIBIT 99.1

To Our Fellow Stockholders,

As Chief Executive Officer I want to extend our appreciation for all your support and thoughtfulness during this very sad and sudden transition after the passing of Clarence Smith. As friends and stockholders, you are the strength we rely on as we sustain and advance the vision that Clarence Smith established in his tenure leading the company.

Our commitment to developing the market for our unique AAGP® (PKX-001) molecule remains firm and supported by the executive team and our partners. The extremely robust molecule is a first-in-class, synthetic glycopeptide with established safety and efficacy in pre-clinical and clinical studies. The molecule is a workhorse that delivers cell protection and helps to control inflammation, in ways that can greatly improve cell therapy strategies and many other disease treatment applications.

ProtoKinetix Inc. holds a stable patent portfolio that protects these unique applications worldwide, including the United States, Europe, UK, Asia and beyond.

Through our current outreach program we have garnered the attention of pharmaceutical companies of various sizes with active market applications with interest to incorporate our glycopeptide in their strategies to address Type 1 Diabetes, cell therapy enhancement, dry-eye and other ophthalmological or topical disorders.

During this season of thanksgiving, I want to express my sincere gratitude to you directly. Your continued support makes our company’s accomplishments possible and allows us to continue down the path to gaining market traction and deliver for you, our stockholders, as Clarence Smith committed to doing.

Let us go forward together in fond memory of our friend.

Mike G

Michael R. Guzzetta

Chief Executive Officer

ProtoKinetix Inc.

109 W. Main St., Dalton, Ohio, 44618

ProtoKinetix.com (330)445-4971

About ProtoKinetix, Incorporated

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this document includes “forward looking statements” withinthe meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, otherthan statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flowsand borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectivesfor future operations, are forward-looking statements. Although we believe that the expectations reflected in these forward-looking statementsare reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guaranteesof future performance. Refer to our risk factors set forth in our reports filed on Edgar. ProtoKinetix disclaims any obligation to updateany forward-looking statement made here.

This document does not constitute or form a part of any offer or solicitation to purchase or subscribefor securities in the United States.

For further information, please contact:

Michael Guzzetta

President, CEO & CFO

Telephone:	330-445-4971
Email:	mguzzetta@protokinetix.com

109 W. Main St., Dalton, Ohio, 44618

ProtoKinetix.com (330)445-4971